(18)Where ESMA has identified that an OTC derivative product is standardised and suitable for clearing but no CCP is willing to clear that product, ESMA should investigate the reason for this.
◷
New version applies from 03/01/2017 — introduced by Regulation (EU) No 600/2014 (MIFIR).
117 provisions change.
Later versions: 01/04/2017, 30/06/2017, 01/01/2019, 17/06/2019, 18/12/2019, 01/01/2020, 18/06/2020, 11/02/2021, 13/02/2021, 28/06/2021, 12/08/2022, 24/12/2024, 17/01/2025.
Recital 18 changes in this version: compare with the current text.